2 Notes on the scope of the guidance
NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.
Topics covered by the partial update are:
Diagnosing heart failure: symptoms and signs, use of serum natriuretic peptides (BNP and NTproBNP).
Pharmacological treatment of heart failure including: aldosterone antagonists, angiotensin II receptor antagonists, angiotensin-converting enzyme inhibitors, beta-blockers, and hydralazine in combination with nitrate.
Disease monitoring in chronic heart failure: serial measurement of circulating natriuretic peptide concentrations, monitoring at home.
Cardiac rehabilitation for heart failure.
How this guideline was developed
NICE commissioned the National Clinical Guideline Centre for Acute and Chronic Conditions to develop this guideline. The Centre established a Guideline Development Group (see appendix A), which reviewed the evidence and developed the recommendations. An independent Guideline Review Panel oversaw the development of the guideline (see appendix B).
There is more information about how NICE clinical guidelines are developed on the NICE website. A booklet, 'How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS' is available.